Group 1 - The core point of the article is that Jiahe Biotech-B (06998) experienced a significant stock price increase of over 17%, reaching 3.76 HKD with a trading volume of 22.33 million HKD, following the announcement of a new clinical trial for its drug GB268 [1][1][1] - The clinical trial is a Phase I study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the PD-1/CTLA-4/VEGF tri-specific antibody GB268 in patients with advanced solid tumors [1][1][1] - GB268 is an independently developed tri-specific antibody by Jiahe Biotech targeting PD-1, VEGF, and CTLA-4 [1][1][1] Group 2 - On April 15, Jiahe Biotech announced that it has submitted a listing application to the Hong Kong Stock Exchange, and Eton Pharmaceuticals will reverse acquire Jiahe Biotech [1][1][1] - In October 2024, Jiahe Biotech and Eton Pharmaceuticals announced a strategic merger, after which the company will be renamed "Eton Jiahe Pharmaceutical Group Limited" [1][1][1] - As part of the merger, Jiahe Biotech will issue new shares to Eton Pharmaceuticals' shareholders, with the equity values of Eton Pharmaceuticals and Jiahe Biotech being 677 million USD and 197 million USD, respectively [1][1][1]
港股异动 嘉和生物-B(06998)午后涨超17% 注射用GB268获批临床 拟开发治疗晚期实体瘤